Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Molecular Cancer Therapeutics|October 29, 2014
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsTomoko Smyth, Kim H T Paraiso, Keisha Hearn, et al.Plos One|October 11, 2011
Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammationAna L Alessandri, Rodger Duffin, Andrew E Leitch, et al.Molecular Cancer Therapeutics|April 27, 2018
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor GrowthGeorge A Ward, Edward J Lewis, Jong Sook Ahn, et al.Molecular Cancer Therapeutics|April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growthKyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.Leukemia & Lymphoma|October 19, 2016
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials GroupMatthew D Seftel, John Kuruvilla, Tom Kouroukis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.Pageof 2